Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nivolumab · 1 trial · 1 indication
Depth of response will be determined for each participant post ide-cel with adjuvant nivolumab indicating if their best overall response is a Complete Response (CR) or stringent Complete Response (sCR). The post-ide-cel disease response assessments will be calculated relative to the participant's pre-ide-cel disease assessment parameters. Responses will be determined per IMWG 2016 response criteria.
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | Nivolumab |
| Name | Type | Description |
|---|---|---|
| Nivolumab | DRUG | 2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information signed by the participant or his/her legally authorized representative 2. Age ≥ 18 years at the time of consent 3. ECOG Performance Status (PS) of ≤ 1 at the time of enrollment. PS mus...
Top 20 of 25 competitors
Nivolumab is being studied for use in Multiple Myeloma, specifically in patients after treatment with idecabtagene vicleucel. It is an investigational small molecule inhibitor targeting PDCD1. The drug is currently in Phase 2 clinical development and is not yet approved for this indication.
Nivolumab targets PDCD1, also known as programmed cell death protein 1. As an inhibitor of this target, it is designed to modulate immune responses. This mechanism is being explored in the context of Multiple Myeloma, where it is being studied as a potential therapeutic option.
Nivolumab is being developed by Atrium Therapeutics, Inc., a company listed under the ticker RNA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Multiple Myeloma. The current development program includes a Phase 2 study.
Nivolumab is in Phase 2 clinical development for Multiple Myeloma. It is an investigational drug, meaning it has not yet received regulatory approval. The ongoing Phase 2 trial is active but not recruiting participants, and it is designed as an uncontrolled, single-arm study.
Nivolumab is being evaluated in a Phase 2 clinical trial with the identifier NCT06523621. The trial is titled 'Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel' and is being conducted in the United States. It enrolls adults aged 18 years and older, with a planned enrollment of one participant.
Nivolumab is the sole name provided for this drug, with no alternative names listed. It is identified by the ChEMBL ID CHEMBL2108738. The drug is being studied under this name in clinical trials for Multiple Myeloma.